Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Asher Begleiter

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 14, 2006
A NAD(P)H:quinone oxidoreductase 1 polymorphism is a risk factor for human colon cancerAsher Begleiter, Donna Hewitt, Andrew W Maksymiuk, et al.
Oncology Reports|May 9, 2009
Inhibition of colon carcinogenesis by post-initiation induction of NQO1 in Sprague-Dawley ratsAsher Begleiter, Kosala Sivananthan, Georgia M Lefas, et al.
Cancer Chemotherapy and Pharmacology|November 14, 2003
Structure-activity study with bioreductive benzoquinone alkylating agents: effects on DT-diaphorase-mediated DNA crosslink and strand break formation in relation to mechanisms of cytotoxicityJeanne Fourie, Frank Guziec, Lynn Guziec, et al.
Drug Target Insights|September 10, 2011
A Model for NAD(P)H:Quinoneoxidoreductase 1 (NQO1) Targeted Individualized Cancer ChemotherapyAsher Begleiter, Nadia El-Gabalawy, Laurie Lange, et al.
Cancer Chemotherapy and Pharmacology|February 28, 2002
The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphoraseJeanne Fourie, Curtis J Oleschuk, Frank Guziec, et al.
Cancer Chemotherapy and Pharmacology|July 13, 2005
Structure-activity study of the interaction of bioreductive benzoquinone alkylating agents with DNA topoisomerase IIBrian B Hasinoff, Xing Wu, Asher Begleiter, et al.
Oncogene|November 14, 2003
Role of the TRAIL/APO2-L death receptors in chlorambucil- and fludarabine-induced apoptosis in chronic lymphocytic leukemiaJames B Johnston, Albert F Kabore, Jeanna Strutinsky, et al.
Oncology Reports|May 11, 2006
Structure-activity studies with cytotoxic anthrapyrazolesAsher Begleiter, Denny Lin, Kimberly K Larson, et al.
Oral Oncology|August 2, 2005
Role of NQO1 polymorphisms as risk factors for squamous cell carcinoma of the head and neckAsher Begleiter, Alia Norman, Darren Leitao, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 14, 2006
A NAD(P)H:quinone oxidoreductase 1 polymorphism is a risk factor for human colon cancerAsher Begleiter, Donna Hewitt, Andrew W Maksymiuk, et al.
Oncology Reports|May 9, 2009
Inhibition of colon carcinogenesis by post-initiation induction of NQO1 in Sprague-Dawley ratsAsher Begleiter, Kosala Sivananthan, Georgia M Lefas, et al.
Cancer Chemotherapy and Pharmacology|November 14, 2003
Structure-activity study with bioreductive benzoquinone alkylating agents: effects on DT-diaphorase-mediated DNA crosslink and strand break formation in relation to mechanisms of cytotoxicityJeanne Fourie, Frank Guziec, Lynn Guziec, et al.
Drug Target Insights|September 10, 2011
A Model for NAD(P)H:Quinoneoxidoreductase 1 (NQO1) Targeted Individualized Cancer ChemotherapyAsher Begleiter, Nadia El-Gabalawy, Laurie Lange, et al.
Cancer Chemotherapy and Pharmacology|February 28, 2002
The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphoraseJeanne Fourie, Curtis J Oleschuk, Frank Guziec, et al.
Cancer Chemotherapy and Pharmacology|July 13, 2005
Structure-activity study of the interaction of bioreductive benzoquinone alkylating agents with DNA topoisomerase IIBrian B Hasinoff, Xing Wu, Asher Begleiter, et al.
Oncogene|November 14, 2003
Role of the TRAIL/APO2-L death receptors in chlorambucil- and fludarabine-induced apoptosis in chronic lymphocytic leukemiaJames B Johnston, Albert F Kabore, Jeanna Strutinsky, et al.
Oncology Reports|May 11, 2006
Structure-activity studies with cytotoxic anthrapyrazolesAsher Begleiter, Denny Lin, Kimberly K Larson, et al.
Oral Oncology|August 2, 2005
Role of NQO1 polymorphisms as risk factors for squamous cell carcinoma of the head and neckAsher Begleiter, Alia Norman, Darren Leitao, et al.
Pageof 2